Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapySix‐minute walk distance · pulmonary arterial hypertension1 finding from 1 reviewPhosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 509 participantsModerate
Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERASix‐minute walk distance · pulmonary arterial hypertension1 finding from 1 reviewPhosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 36 participantsLow
Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placeboSix‐minute walk distance · pulmonary arterial hypertension1 finding from 1 reviewPhosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes onlyno estimate extracted8 studies · 880 participantsModerate
Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i vs placeboSix‐minute walk distance · people with pulmonary hypertension group 2 ‐ 41 finding from 1 reviewPhosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes onlyno estimate extracted1 study · 106 participantsModerate
Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placeboSix‐minute walk distance · people with pulmonary hypertension due to lung disease1 finding from 1 reviewPhosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes onlyno estimate extracted5 studies · 350 participantsHigh
Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i vs placeboSix‐minute walk distance · people with pulmonary hypertension due to left‐heart disease1 finding from 1 reviewPhosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 284 participantsModerate
Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i vs placeboSix‐minute walk distance · people with pulmonary hypertension due to CTEPH2 findings from 1 reviewPhosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes onlyno estimate extracted1 study · 19 participantsLowPhosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 227 participantsModerate